"Do I qualify for Ozempic?" is one of the most Googled health questions of the past two years. And the answer is frustratingly complicated — because it depends on what you mean by "qualify," which medication you're asking about, and whether you're talking about FDA approval, insurance coverage, or what a doctor is willing to prescribe.

Let's cut through the confusion. Here's a straightforward guide to GLP-1 eligibility based on where your BMI falls, what the FDA actually says, and what the real-world prescribing landscape looks like in 2025.

The Official FDA Criteria

The FDA has approved specific GLP-1 medications for chronic weight management with the following criteria:

Wegovy (semaglutide 2.4mg) and Zepbound (tirzepatide):

  • BMI ≥ 30 (obesity) — no additional criteria needed, OR
  • BMI ≥ 27 (overweight) WITH at least one weight-related comorbidity: type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea

Ozempic (semaglutide 0.5–1mg) and Mounjaro (tirzepatide): These are FDA-approved specifically for type 2 diabetes, not weight loss. However, they're widely prescribed off-label for weight management because they contain the same active ingredients as their weight-loss counterparts. For a comparison of these medications, see our Ozempic vs. Wegovy vs. Mounjaro breakdown.

That's the official story. Here's the real one.

The Off-Label Reality

Off-label prescribing — using a medication for a purpose other than its FDA-approved indication — is legal, common, and a normal part of medical practice. Roughly 20% of all prescriptions written in the U.S. are off-label. In the GLP-1 space, off-label prescribing has become extremely widespread. Many telehealth providers and weight-management specialists prescribe semaglutide or tirzepatide to patients with BMIs below 27, particularly those who:

  • Carry excess visceral fat despite a "healthy" BMI
  • Have metabolic risk factors (prediabetes, insulin resistance, elevated triglycerides)
  • Have struggled to lose weight through diet and exercise alone
  • Are motivated and informed about the medication's effects

This doesn't mean anyone can or should get a GLP-1 prescription. But it does mean the BMI 30 threshold isn't the hard line many people assume it is.

What to Expect by BMI Range

Your starting BMI meaningfully affects how much weight you're likely to lose, how the medication feels, and how the results manifest. Here's a realistic preview for each range.

BMI Below 18.5: Not a Candidate

If your BMI is under 18.5, you are underweight by clinical standards and GLP-1 therapy is not appropriate. These medications reduce appetite and caloric intake — exactly the opposite of what an underweight person needs. No responsible provider should prescribe them in this range, and using them could be genuinely dangerous.

If you're underweight and struggling with body image or disordered eating, please talk to a healthcare provider who specializes in eating disorders. The National Eating Disorders Association (NEDA) helpline is available at 1-800-931-2237.

BMI 18.5–24.9: The "Already Healthy" Zone

This is where things get nuanced. Your BMI is technically in the healthy range, so you won't meet FDA criteria and insurance almost certainly won't cover GLP-1 for weight loss. But "healthy BMI" doesn't mean "optimal body composition" — and many people in this range have legitimate reasons to want to lose 5–15 lbs.

What to expect:

  • Weight loss of roughly 5–10% of body weight (8–18 lbs for a 170-lb person)
  • Lower doses often sufficient (0.5–1.0mg semaglutide vs. the full 2.4mg Wegovy dose)
  • Changes are subtle but visible: leaner face, tighter midsection, more definition
  • Shorter timeline — 2–4 months rather than 12+
  • Framing is body recomposition, not major weight loss
  • Muscle preservation requires active effort (resistance training + high protein)

For a deeper dive into this use case, read our article on GLP-1 for the last 10 pounds.

BMI 25–29.9: The Overweight Range

This is the sweet spot for GLP-1 therapy in many ways. You're above the healthy BMI threshold, the medical rationale is clearer, and the results are noticeable without being extreme. If you have a comorbidity (and many people in this range do — high blood pressure, prediabetes, or elevated cholesterol are common), you meet FDA criteria for Wegovy or Zepbound.

What to expect:

  • Weight loss of 12–17% of body weight (25–40 lbs for a 200-lb person)
  • Timeline: 6–10 months to reach projected weight
  • Clearly visible transformation — face, waist, and overall silhouette all change
  • BMI often moves from overweight into the healthy range — a meaningful clinical milestone
  • Health markers typically improve: blood pressure, fasting glucose, lipid profile
  • Insurance coverage is possible, especially with a documented comorbidity

This is the range where people hear "wow, you look great — what have you been doing?" from coworkers and friends. It's also where the clinical data is strongest, since the STEP trial participants included many people in this BMI range. Check our GLP-1 weight loss timeline for a month-by-month breakdown.

BMI 30–34.9: The Obese Range

You clearly meet FDA criteria. Insurance coverage is more likely (though still not guaranteed for the weight-loss indications). The transformation at this level is dramatic and the health benefits are substantial.

What to expect:

  • Weight loss of 15–21% of body weight (40–60 lbs for a 250-lb person)
  • Timeline: 8–12 months for full projected loss
  • Major visible changes — face shape changes significantly, midsection reduces substantially, overall body proportions shift
  • Significant health improvements: the STEP trials showed meaningful reductions in blood pressure, HbA1c, waist circumference, and inflammatory markers at this level of loss
  • The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide in people with established cardiovascular disease

BMI 35+: Maximum Transformation

At BMI 35 and above, GLP-1 therapy produces the most dramatic results. You unambiguously meet all eligibility criteria, and insurance coverage — while still variable — is most likely in this range.

What to expect:

  • Weight loss of 18–24% of body weight
  • Timeline: 10–14 months for full projected loss
  • Transformative changes in appearance, mobility, and health
  • Many people begin seeing noticeable changes within the first 4–8 weeks
  • Life-changing improvements in conditions like sleep apnea, joint pain, and diabetes risk
  • Some people in this range may also be candidates for bariatric surgery — GLP-1 can be a first step or an alternative

When GLP-1 Therapy Is NOT Appropriate

Regardless of BMI, GLP-1 medications are not recommended for:

  • People who are underweight (BMI < 18.5). Further weight loss would be harmful.
  • People with active eating disorders. Appetite suppression can reinforce anorexic or restrictive patterns. If you have a history of anorexia, bulimia, or ARFID, discuss this with a specialist before considering GLP-1.
  • Pregnant or breastfeeding women. GLP-1 medications should be stopped at least 2 months before planned conception (semaglutide has a long half-life).
  • People with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This is a labeled contraindication based on animal studies.
  • People with a history of pancreatitis should discuss risks carefully with their provider.

Questions to Ask Your Doctor

If you're considering GLP-1 therapy, here are the questions worth raising with a healthcare provider:

  1. "Based on my BMI, body composition, and health history, am I a good candidate for GLP-1 medication?"
  2. "Which medication do you recommend — semaglutide or tirzepatide — and why?"
  3. "What dose would you start me at, and what's the titration schedule?"
  4. "Will my insurance cover this? If not, what are my options (manufacturer savings, compounded versions)?" — see our cost guide for more detail
  5. "What side effects should I expect, and when should I contact you about them?"
  6. "What's the plan for when I reach my goal weight? How do we manage the transition off medication?"
  7. "Should I be doing anything specific regarding diet, exercise, or protein intake while on the medication?"

See Your Projected Transformation

Before you make any decisions about medication, it can help to see what GLP-1 weight loss would actually look like on your body. The MeOnGLP tool uses your photo, height, weight, age, and sex to project your transformation based on clinical data for your BMI range. It takes about a minute and gives you a tangible preview of what the numbers actually mean on your frame.

It's not medical advice — it's motivation. And sometimes that's exactly what you need to start a real conversation with your doctor.